OTLK — Outlook Therapeutics
Median target
$1.6
calls from the last 12 months
Implied return
+134.9%
median target vs. price
Coverage
1 analysts · 2 calls
updated in the last 12 months
Consensus
0/1/00 net
Buy / Hold / Sell
Which analysts are behind OTLK's consensus?
See every current rating, price target and the analysts' track records for Outlook Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 1 analysts with calls on OTLK updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
OTLK elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-12 | Insiders | Sukhtian Ghiath M. +1Director | Insider purchase | 2.5M sh @ $0.99 | $2.5M |
| 2026-07-29 | Insiders | Sukhtian Faisal GhiathDirector | Insider purchase | 95.4K sh @ $1.05 | $100K |
More: insider activity · executive branch · trending